The Medical Advisory Board of the Pulmonary Fibrosis Foundation (PFF)Â recently released an announcement regarding therapies based on stem cells for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred…
Researchers at the Medical School of Nanjing University in China recently published in the journal Respirology findings that reveal how shorter telomeres in chromosomes are associated with a poor survival in patients with idiopathic pulmonary fibrosis (IPF). The study is entitled “Association between telomere…
Dr. Claudia A. Staab-Weijnitz and Dr. Oliver Eickelberg at the Comprehensive Pneumology Center in the University of Munich are studying a new drug target for idiopathic pulmonary fibrosis (IPF) that addresses a protein potentially involved in the pathway of IPF pathogenesis. By attenuating the protein in a model of IPF,…
Clinical stage biotech company Promedior Inc. will present data from its ongoing phase 2 clinical trial of their lead investigational therapy candidate for myelofibrosis at the 20th Congress of the European Hematology Association (EHA) taking place between June 1st and 14th in Vienna, Austria. The presentation on PRM-151, which is also being…
Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that repurposes and reformulates already approved drugs for larger markets such as cystic fibrosis, recently announced that the United States Patent Office (USPO) has issued United States Patent No. 9029385 for its patent application, “Compositions and Methods for Treating Fibroproliferative Disorders.”…
According to a recent study published in the journal CHEST, the official journal of the American College of Chest Surgeons, several mortality-risk prediction models used in assessing mortality at 1-year in patients with idiopathic pulmonary fibrosis may also be a viable option in gauging short-term mortality in…
ProMetic Life Sciences Inc. recently validated the potential for its experimental drug target PBI-4050 to treat patients with idiopathic pulmonary fibrosis. Two presentations at the 2015 European Renal Association Annual Meeting identified that PBI-4050 reduces fibrosis in human cells. “Our data correlates the regulation activity of PBI-4050 on key fibrotic…
John McManus, Chief Executive Officer, presented an outline of Aeolus’ development programs with a focus on the company’s progress regarding its contract with the Biomedical Advanced Research and Development Authority (“BARDA”), during the LD Micro Invitational meeting that took place last December in Los Angeles. The details of that meeting were recently…
Building a new set of lungs for patients with pulmonary fibrosis is becoming closer to reality as a result of cutting-edge research in the field of tissue engineering. At the forefront of this endeavor is Cheryl Nickerson, PhD, an expert in infectious diseases and vaccinology at Arizona State University Biodesign Institute.
RestorGenex Pharmaceuticals, a biotechnology company developing innovative therapeutics for a large spectrum of diseases, including cancer and those of the dermatology and ophthalmology spectrum, recently presented at the American Thoracic Society International Conference in Denver, Colorado their latest results using RES-529 as a potential treatment for idiopathic pulmonary fibrosis.
Get regular updates to your inbox.
